TIN2 Functions with TPP1/POT1 To Stimulate Telomerase Processivity

TIN2 is an important regulator of telomere length, and mutations in TINF2, the gene encoding TIN2, cause short-telomere syndromes. While the genetics underscore the importance of TIN2, the mechanism through which TIN2 regulates telomere length remains unclear. Here, we tested the effects of human TIN2 on telomerase activity. We identified a new isoform in human cells, TIN2M, that is expressed at levels similar to those of previously studied TIN2 isoforms.

While mouse cells express a single TIN2 isoform, human cells express short and long alternatively spliced isoforms, TIN2S and TIN2L (Fig. 1A). Both isoforms contain the shelterin interacting domains that bind TRF1, TRF2, and TPP1, as well as the small domain of unknown function that is mutated in patients with short-telomere syndromes. TIN2L contains the entire TIN2S sequence (residues 1 to 354), along with a  Table S1 in the supplemental material), with degrees of conservations indicated on a color scale ranging from white (score of 0 [not conserved]) to navy (score of 10 [highly conserved]). (B) Expression cassettes used in this study. All cassettes were expressed under the control of the cytomegalovirus (CMV) promoter in the pcDNA5/FRT backbone. Telomerase assay cell lines were generated as described in Materials and Methods. (C) Western blot of individually transfected TPP1, POT1, and TERT cDNAs next to telomerase assay cell lines with numbers corresponding to those in panel B. FLAG bands above POT1 are unidentified but may represent TERT degradation products. (D) Telomerase assays were stopped at 5, 10, 20, and 40 min for each cell line. Telomere repeats are indicated by ϩ1, ϩ2, etc. LC, loading and purification control.
C-terminal extension that contains highly conserved residues (Fig. 1A). Recent evidence suggests that the longer isoform is functionally different from TIN2S (32), but TIN2S is the most widely studied isoform.
To elucidate the mechanism of TIN2 regulation of telomere length in human cells, we set out to test the biochemical functions of the TIN2 isoforms in the context of the TPP1/POT1 telomerase processivity complex. We found that TIN2 stimulates telomerase processivity in a TPP1/POT1-dependent manner. Further, we found a third isoform, TIN2M, expressed in human cells. Each TIN2 isoform can localize to telomeres, maintain telomere integrity, and stimulate telomerase processivity. Together with the requirement of TIN2 for TPP1/POT1 function in vivo, these data implicate TIN2 as a part of the telomerase processivity complex, forming a functional shelterin subcomplex. This is the first evidence of TIN2 having a direct role in regulating telomerase, suggesting that it may do more than simply bridge the shelterin components at the telomere.

RESULTS
To understand the mechanism of TIN2 in telomere length regulation, we examined whether TIN2 might directly affect telomerase activity. TIN2 interacts directly with the TPP1 component of the TPP1/POT1 telomerase processivity complex that binds telomerase through the TPP1 TEL patch domain (18,(20)(21)(22)33). To examine whether TIN2 affects telomerase activity or processivity, we reconstituted active telomerase complexes in a cell extract-based system overexpressing telomerase to measure telomerase activity and processivity in vitro (18)(19)(20)34). We adapted this previously published extract-based system (20) to generate cells constitutively expressing telomerase (TERT/ TR), TPP1, and POT1 and then introduced TIN2 by transient transfection.
For reproducible overexpression of the protein components, we created a polycistronic expression cassette containing FLAG-TPP1, FLAG-POT1, and FLAG-TERT separated by 2A peptides (Fig. 1B). As a negative control, we mutated the TPP1 TEL patch (TPP1 E169A/E171A) (20), referred to here as TPP1 TEL , to test whether any effects of TIN2 are mediated through TPP1/POT1 (Fig. 1B). We constructed the assay cell lines by first generating a clonal cell line overexpressing telomerase RNA (TR) in 293TREx FLP-in cells, into which we integrated the expression cassettes at a unique genomic locus using the FLP-in system. The resulting cell lines are referred to here as TPP1/POT1/TERT and TPP1 TEL /POT1/TERT (Fig. 1B to D). Exogenous TIN2 was introduced to these cell lines by transient transfection (see Materials and Methods). We note that in this assay, relative to the exogenous proteins, levels of endogenous shelterin proteins are too low to affect the biochemical assays, as evidenced by the observation that endogenous TPP1 is unable to compensate for the processivity defects of TPP1 TEL in the TPP1 TEL /POT1/TERT cell line (Fig. 1D).
To examine the effects of TIN2 on telomerase activity, we initially transfected a myc-tagged full-length TINF2 gene, inclusive of introns, to express both alternatively spliced TIN2 isoforms. Telomerase assays showed increased processivity in TPP1/POT1/ TERT cells transfected with myc-TINF2 compared to the green fluorescent protein (GFP) control (Fig. 2B), suggesting that TIN2 enhances telomerase processivity to a level above that resulting from effects of TPP1/POT1 alone. Surprisingly, Western blotting performed with these lysates showed three distinct bands, instead of the expected two bands corresponding to TIN2S and TIN2L ( Fig. 2A). We deduced that the third band may correspond to a new isoform and, further, that any of the three isoforms could be responsible for the increased processivity in myc-TINF2 lysates.
Identification of a new TIN2 isoform, TIN2M. To further examine the TIN2 isoforms, we engineered an N-terminal myc tag at the endogenous TINF2 locus in 293T cells using CRISPR/Cas9 genome editing (Fig. 3A). Western blots on several edited clones again showed the three distinct bands (Fig. 3B), suggesting that the third band did not represent an artifact of the overexpression construct. To identify these bands, we transfected myc-TINF2 alongside cDNA constructs expressing myc-TIN2S or myc-TIN2L (Fig. 3C), which revealed that the unknown band fell between the known isoforms, running at ϳ47 kDa (Fig. 3C).
To test whether this band corresponds to an alternatively spliced TIN2 isoform, we used a modified 3= rapid amplification of cDNA ends (3=RACE) assay with PacBio sequencing to identify all full-length transcripts in human and mouse cells. In 293T cells, TIN2S and TIN2L cDNAs were identified along with a third major isoform, which encodes a protein with the expected molecular weight for the unknown protein. We termed this isoform "TIN2M" for "TIN2 medium." TIN2M results from retention of the last intron, between exons 8 and 9, which encodes 13 amino acids of unique sequence ( 408 VSGKEQKAGKGDG 420 ) before reaching a stop codon ( Fig. 3D and E). TIN2M was present at similar levels in four other human cell lines (HeLa, K562, RPE-1, and a newly derived lymphoblastoid cell line [LCL]), suggesting that it is commonly expressed.
Sequence read counts indicated that TIN2M and TIN2L mRNAs were expressed at similar levels, while TIN2S had 2-fold-greater representation than each of the others (Fig. 3D). These ratios are not always reflected in Western blots ( Fig. 3B and C) as the mRNA abundance and protein levels may be discordant due to posttranslational regulation. Additionally, TIN2L has shown poor solubility and its detection varies depending on the protein extraction method (35).
In addition to the three major isoforms in human cells, we identified a number of additional recurrent exon skipping, intron retention, and alternative polyadenylation site usage events, including exon 2 skipping, described previously (36) (Fig. 3D). We found that two different mouse strains (C57BL/6 and CAST/EiJ) expressed just one TIN2 isoform that is most similar to TIN2L, as previously described (35,37) (not shown).
Evidence for expression of TIN2M was also found in data publicly available from PacBio IsoSeq from MCF-7 breast cancer cells (http://www.pacb.com/blog/data-release -human-mcf-7-transcriptome/). Additionally, genome-wide ribosome profiling data from GWIPS-viz showed ribosome peaks present in the unique coding region of the TIN2M-retained intron (38). TIN2M and TIN2L contain the recently identified CK2 phosphorylation site (32), but TIN2S does not. All three of the expressed isoforms contain the documented cluster of telomere syndrome patient mutations and the other known interaction domains.
All three TIN2 isoforms localize to telomeres. TIN2S and TIN2L have been demonstrated to localize to telomeres in vivo (12,35). To determine whether TIN2M also localizes to telomeres, we stably expressed cDNA encoding myc-tagged TIN2S, TIN2M, or TIN2L in HeLa Flp-in cells. Using indirect immunofluorescence, we found that all three isoforms showed discrete foci that colocalized with TRF2, indicating that each localizes to telomeres in vivo (Fig. 4). This demonstrates that all three TIN2 isoforms may be found at endogenous telomeres in human cells and that the different C-terminal domains do not appear to affect telomeric localization.
Since all of the TIN2 isoforms also contain the patient mutation cluster (Fig. 1A), we tested whether mutant TIN2 is defective in telomeric localization. TIN2S with patient mutations K280E, R282S, and R282H was previously shown to localize to telomeres (39,40), but localization in TIN2M or TIN2L with mutations has not been reported. We expressed a well-studied patient mutation, K280E, in each of the three isoforms and observed telomeric localization of all three isoforms with this mutation (Fig. 4). The results suggested that any of these three isoforms could mediate the dominantnegative telomere-shortening effect of the patient mutations in vivo.
TIN2M and TIN2L rescue telomere damage foci. TIN2 is an integral part of the shelterin complex, and disruption of shelterin results in a DNA damage response at telomeres, termed telomere dysfunction-induced foci (TIFs). Removal of endogenous TIN2 elicits a TIF phenotype that can be rescued by reintroducing TIN2 (28,31). To determine whether each isoform can rescue this phenotype, we depleted endogenous TIN2 with short hairpin RNA (shRNA) in the HeLa myc-TIN2 cell lines described above using HeLa GFP as a control. The TIN2 shRNA (shTIN2) resulted in ϳ90% knockdown of endogenous TIN2 compared to a nontargeting shRNA (shNT) in the GFP cell line (Fig.  5A) and did not target exogenous myc-TIN2 isoforms as detected by Western blotting (Fig. 5B).
In control cell lines, TIN2 knockdown significantly increased levels of TIFs compared to the nontargeting control results, as measured by colocalization between TRF2 and 53BP1 ( Fig. 5C and D). This was reflected by a higher mean number of TIFs per nucleus as well as by a higher proportion of cells having a large number of TIFs. Overexpression of TIN2S prevented this increase in TIFs, and we found that TIN2M and TIN2L also effectively rescued TIFs when endogenous TIN2 was knocked down (Fig. 5D). This suggests that the three isoforms are individually capable of performing the telomere maintenance roles seen with TIN2 ( Fig. 5C and D). TIN2 cooperates with TPP1/POT1 to stimulate telomerase processivity. Preliminary experiments showed that the TINF2 full-length gene stimulated telomerase processivity, and we have demonstrated that each isoform localizes to and functions at telomeres in vivo. We next examined whether one of the isoforms might be responsible for the stimulation of telomerase observed with myc-TINF2. Each of the three TIN2 isoforms reproducibly coimmunoprecipitated with TPP1/POT1 and TERT in reciprocal pulldown of either myc-TIN2 or FLAG-TPP1/POT1/TERT ( Fig. 6 and data not shown). The K280E mutation caused no major change in the coimmunoprecipitation of TPP1/POT1 and TERT in any of the three isoforms ( Fig. 6) as had been shown previously for TIN2S (39,41). Telomerase activity was detected in these coimmunoprecipitations, suggesting that telomerase complexed with TIN2 was active (data not shown). In our hands, TIN2 coimmunoprecipitations showed robust TERT coimmunoprecipitation even in the TPP1 TEL mutant, despite previous reports that TEL patch mutations decreased TPP1-TERT interactions by about 40% (20). We conclude that all three isoforms of TIN2 were interacting with TPP1/POT1 in complex with active telomerase and that this complex was not disrupted by the TIN2-K280E patient mutation or the TPP1 TEL mutation.
Using our extract-based telomerase reconstitution system, we transfected TPP1/ POT1/TERT cells with each isoform and found reproducible 10% to 20% increase in stimulation of telomerase processivity with each of the three N-terminally tagged isoforms (Fig. 7). TIN2 is important for TPP1/POT1 function in the cell; here, we report evidence of a biochemical function of TIN2 in telomerase processivity stimulation. To We found no stimulation of telomerase processivity in either of these lysates (Fig. 7C), suggesting that the stimulation was dependent on TPP1/POT1. Our results indicate that TIN2 cooperates with TPP1/POT1 to stimulate telomerase processivity. Because all three TIN2 isoforms stimulated telomerase processivity in a TPP1/POT1dependent manner, we tested whether each of patient mutations TIN2-K280E, TIN2-R282S, TIN2-R282H, and TIN2-K280X affects this function of TIN2. In some instances, we found that TIN2 mutants were deficient at stimulating telomerase activity but that this result was variable both in whole-cell lysates and in TIN2 coimmunoprecipitations. Because the TINF2 mutations are dominant negative in vivo, we tried coexpressing wild-type TIN2 with a mutant TIN2, but we were not able to detect a change in processivity stimulation in this in vitro setting. Although the patient mutations did not reproducibly affect telomerase processivity in this assay, it is possible that they have important processivity defects in vivo.

DISCUSSION
Our data provide novel biochemical evidence that TIN2 stimulates telomerase processivity in a TPP1/POT1-dependent manner. TIN2 may function by stabilizing the TPP1/POT1 interaction with telomerase, as it relies on TPP1-TERT interaction. This suggests that TIN2 is an integral part of what we refer to as the "TIN2/TPP1/POT1 processivity complex." This previously unknown role of TIN2 isoforms in telomerase processivity stimulation adds to our understanding of TIN2's role in telomere length regulation. While all three isoforms were able to stimulate telomerase activity in vitro, further work may uncover differences in the regulation of their activities in vivo.  TIN2L  TIN2M  TIN2S   TERT   POT1  TPP1   TIN2L  TIN2M  TIN2S   TPP1/POT1  TPP1 TEL /POT1   GFP  TIN2S  TIN2M  TIN2S-K280E  TIN2M-K280E   TIN2L  TIN2L-K280E   TIN2S  TIN2M  TIN2S-K280E  TIN2M-K280E   TIN2L  TIN2L-K280E   51  TIN2 cooperates with TPP1/POT1 to stimulate telomerase processivity. All three TIN2 isoforms formed a stable complex with TPP1/POT1 and TERT, and addition of TIN2 further stimulated telomerase processivity over the level seen with TPP1/POT1 alone. This stimulation of processivity required TPP1 and POT1, as there was no stimulation in cells expressing TPP1 TEL patch mutants or TERT alone ( Fig. 7B and C). TIN2 could enhance telomerase processivity by improving the TPP1/POT1 complex stability or its interaction with telomerase, by promoting the telomeric single-stranded DNA (ssDNA) interaction of the complex, or by some combination of the two (Fig. 8A).
Interestingly, the identification of TIN2 as an additional component to an already known processivity complex is reminiscent of recent findings in Tetrahymena. The Tetrahymena telomerase holoenzyme structure (42) revealed two unknown subunits, Teb2 and Teb3, that interact with the previously defined Teb1-p50 processivity complex. The addition of these proteins to in vitro reactions further stimulated telomerase processivity, possibly by stabilizing the completly assembled processive enzyme complex (43). Our results with TIN2 are analogous to this finding in Tetrahymena, suggesting that TIN2 binding to TPP1/POT1 stabilizes the complex and thus promotes processivity.
The TIN2/TPP1/POT1 heterotrimer likely affects both telomerase and replication fork progression. Considering TIN2/TPP1/POT1 to be a telomere-specific ssDNA binding protein (SSB) complex helps explain the defects in telomere replication that have been reported for both POT1 and TPP1 knockdowns and mutants (12,13,39,46,47). While most diagrams draw TPP1/POT1 bound to the G-strand overhang at telomeres, this telomere-specific SSB complex can also bind the telomeric G strand exposed during DNA replication (Fig. 8B) (29,48). TPP1 and POT1 have both been reported to facilitate DNA replication through telomeric tracts (49)(50)(51)(52). POT1 mutants that cannot bind DNA cause telomere replication fork stalling, fragile telomeres, and ATR activation (52), possibly due to ssDNA exposure at the telomeric replication fork. TIN2 knockdown (29) and mouse mutants (53) also cause an ATR-mediated DNA damage response. Taken together, the data suggest that telomeric TIN2/TPP1/POT1 may participate directly in replication fork progression through the telomere and that perturbation of this function may lead to replication fork collapse and activation of ATR. TINF2 mutations and the role of the TIN2 C terminus in telomere length regulation. The mutations in TINF2 in short-telomere syndrome patients mostly cluster in a TIN2 domain of unknown function in exon 6 near the C terminus of TIN2 (25, 26) (Fig. 1A). Genetic evidence strongly supports the idea of a dominant-negative mechanism for the mutant TIN2 proteins, including their autosomal dominant inheritance, stable expression, clustering of disease-associated alleles within the coding sequence, and evidence of selection against the mutant proteins in the hematopoietic lineage in vivo (54). Experimental evidence supports the existence of such a dominant-negative mechanism (40), but the molecular nature of this effect is not well understood.
We found that all three TIN2 isoforms form a complex with TPP1/POT1, stimulate telomerase processivity, localize to telomeres, and maintain telomere integrity. Interestingly, these isoforms differ only in their C-terminal domains. TIN2 can be roughly divided into two regions: the shelterin-interacting region in the N terminus and the C-terminal region that includes the patient mutation cluster, the variable C-terminal extensions of TIN2M and TIN2L, and several other interaction sites and modifications (32,44,55,56) (Fig. 1A). The structure is known for much of the shelterin-interacting region, including the N-terminal TRF2/TPP1 binding domain (TIN2 1-202 ) (57) and the short TRF1-interacting motif (TIN2 256 -276 ) (58). There is no structural information, however, regarding the C-terminal region, including both the mutation hot spot and the variable C-terminal extension. Interestingly, the C-terminal extension contains two cell cycle-regulated RSK2 phosphorylation sites (S295 and S333) (56) and a highly conserved region with a CK2 phosphorylation site at S396 (32), while the patient mutation hot spot overlaps a canonical PXVXL HP1␥ binding site (55). Additionally, some of the patient mutations, such as K280X, are truncations that generate a short stable protein missing the entire C-terminal region (59). The effects of these binding and phosphorylation events are not yet understood. The TIN2 C terminus may function through binding a novel partner or through a conformational or structural role. Future studies focusing on the C-terminal region of TIN2, especially the conserved region in the C-terminal extension, may reveal novel mechanistic insights that were missed in previous work on TIN2 mutations and telomere shortening.

MATERIALS AND METHODS
Expression constructs. TIN2S cDNA was purchased from Invitrogen (Ultimate ORF Clone IOH80607) in pENTR221. A synthetic gBlock (IDT) containing the downstream TIN2 sequence was used in Gibson assembly to generate TIN2L with silent mutations for shRNA resistance. TIN2M was cloned by reverse transcription-PCR (RT-PCR) of endogenous transcripts. TIN2S, TIN2M, and TIN2L were amplified with primers containing HindIII and NotI restriction sites and an N-terminal myc tag and were cloned into pcDNA5/FRT. TINF2, the TIN2 full-length gene inclusive of introns, was cloned into pcDNA5/FRT as described previously (54). Patient mutations were generated by site-directed mutagenesis. The sequences of all constructs and mutants were verified by Sanger sequencing at the Johns Hopkins University (JHU) Synthesis & Sequencing Facility.
For immunofluorescence experiments, the indicated pcDNA5/myc-TIN2 cDNA construct or pcDNA5/ GFP was integrated into HeLa FLP-in cells by the use of a FLP-in system (Invitrogen) and hygromycin-TIN2 Stimulates Telomerase Processivity Molecular and Cellular Biology resistant clones were pooled for downstream analysis. For TIF experiments, where indicated, cells were also transduced with pGIPZ lentiviruses containing a nontargeting shRNA (Dharmacon catalog no. RHS4346) or shRNA targeting exon 9 of TIN2 (Dharmacon catalog no. V3LHS_401958) at a multiplicity of infection (MOI) of 0.3 and were then selected with puromycin. Cells were analyzed within 2 weeks of transduction to avoid silencing of the shRNA. TIN2S and TIN2M cDNAs have exogenous 3= untranslated region (3=UTR) sequences and therefore are shRNA resistant; TIN2L was engineered with silent mutations for shRNA resistance in exon 9. Telomerase assays. Telomerase assay cell lines were generated in 293 TREx FLP-in cells (Invitrogen catalog no. R78007) as described previously (63). Briefly, parental cells were transduced with a telomerase RNA (TR) lentivirus, selected, and cloned by limiting dilution. Then, the TPP1/POT1/TERT or TPP1 TEL / POT1/TERT construct was integrated at a single site in a TR-overexpressing clone using the Flp-in system (Invitrogen). For telomerase assays, 5 ϫ 10 5 cells of the respective cell lines were plated in each well of a 6-well dish. The next day, 2.5 g of the indicated TIN2 or GFP construct was transfected with Lipofectamine 2000 (Invitrogen catalog no. 11668019) following the manufacturer's protocol. After 48 h, cells were lysed in 100 l 1ϫ CHAPS {3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate} lysis buffer and clarified by centrifugation. Telomerase assays were performed using 5 l of clarified cell lysate as described in reference 63. Assays were quantitated in ImageQuantTL (GE Healthcare) using the 15ϩ method as described previously (20). Statistical analysis was performed in GraphPad Prism.
Multiple-sequence alignments. TIN2 sequences from vertebrates with known or predicted TIN2 proteins were obtained from NCBI. The longer isoform was chosen for organisms with multiple reported isoforms. Sequences were uploaded and processed using PRALINE multiple-sequence alignment with the default parameters (64,65). To make the sequence conservation heat map, the PRALINE output was imported into Microsoft Excel, and the alignment scores (0 to 10) for human TIN2 are indicated on a color-coded scale ranging from white (score of 0 [not conserved]) to navy (score of 8, 9, or 10 [highly conserved]). The sequences used are listed in Table S1 in the supplemental material.
CRISPR editing. Guide RNAs were selected using the Zhang Lab CRISPR design tool (http://crispr .mit.edu/). For endogenous tagging of TIN2, the guide sequence (CGCCACCAGGGGCGTAGCCATGG) was cloned into pX459-U6-Chimeric_BB-CBh-hSpCas9-2A-Puro. The repair template was generated by PCR from the cloned myc-TINF2 construct. A 1-g volume of Cas9-2A-PuroϩTIN2 guide was transfected into 293T cells with 10 molar equivalents of the repair template using XtremeGENE9 (Roche catalog no. 6365787001). The cell population was enriched for edited clones with puromycin, subjected to cloning by limiting dilution, and screened by PCR and restriction digests. Clones with positive results were examined by Western blotting. While we found many edited clones, 293T cells are hypotriploid with an unstable karyotype, and we observed high levels of endogenous Myc expression that interfered with Western blotting for myc-tagged TIN2. These limiting factors make it difficult to further study TIN2 in these knock-in cell lines.
3=RACE and PacBio. The 3=RACE and sequencing assays were performed using samples from five human cell lines (293T, HeLa, RPE-1, K562, and LCL) and two mouse samples (CAST/EiJ mouse embryonic fibroblasts [MEFs] and C57BL/6 liver). All mouse samples were obtained with approval by the Institutional Animal Care and Use Committee at the Johns Hopkins University School of Medicine. We combined 3=RACE with Pacific Biosciences (PacBio) single-molecule, real-time (SMRT) sequencing to cover transcripts from the 5'UTR through the poly(A) tail. First, we isolated mRNA from Ͼ10 6 cells using an RNeasy kit (Qiagen) per manufacturer instructions with QIAshredder spin columns (Qiagen), on-column DNase digestion (Qiagen) to remove any genomic DNA, and an RNA cleanup step. We then reverse transcribed 1.5 g mRNA with an oligo(dT 20 ) primer and an adapter sequence (GACTCGAGTCGACATCG-T 20 ) using a SuperScript III first-strand synthesis kit (Qiagen). A 5-l volume of the resulting cDNA was amplified with Hot Start Phusion polymerase (Thermo) using primers corresponding to the adapter and the 5=-UTR (CGGCGACGTTTAAAGCTGA). A total of 3 to 5 replicate PCRs were combined, purified with a QIAquick PCR purification kit (Qiagen), and submitted to the Johns Hopkins Deep Sequencing & Microarray Core Facility for sequencing. Quality control was performed on a 1:200 dilution of samples using a Bioanalyzer high-sensitivity DNA assay (Agilent). Products were size selected for the anticipated size range of 1 to 3 kb. One SMRT cell was sequenced per sample. Sequencing reads were processed using SMRT Analysis v4.0 software, aligned to chromosome 14 with HISAT2, and assembled into potential transcripts using StringTie (66,67). StringTie was first run for individual samples using the default settings with the exception that the minimum isoform fraction was set to 0.01 instead of 0.1. To build a gene model for all human reads, StringTie-merge was run with the minimum isoform fraction set to 0.05. HISAT2 and StringTie results were viewed in IGV (68,69).
Immunofluorescence. For TIN2 localization, HeLa FLP-in cells were plated in chamber slides. The following day, the cells were washed with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA) for 20 min. Slides were washed with PBS, treated with 0.5% Triton-PBS for 15  For TRF2/53BP1 colocalization analysis, cells were seeded in chamber slides and, 2 days later, samples were processed for immunofluorescence staining. Before fixation was performed, cells were subjected to in situ fractionation as described previously (70). After several washes with cold PBS were performed, the cells were fixed in 3% paraformaldehyde-2% sucrose-PBS for 10 min at room temperature, washed in PBS, and permeabilized in cold 0.3% Triton-PBS for 8 min. After three PBS washes, the slides were blocked in 3% goat serum-1 mg/ml bovine serum albumin (BSA)-PBS for 30  All stained slides were washed three times with PBS and coverslips were mounted with Vectashield containing DAPI (4=,6-diamidino-2-phenylindole) after the secondary antibody incubation. Images were acquired on a Nikon Eclipse NI-E microscope using a PlanApo 60ϫ objective and NIS-Elements software.
TIF analysis. Colocalization analysis was performed using Nikon NIS-Elements software. Nuclei were identified using thresholding as regions of interest and were excluded if they were not completely in the field of view. Thresholding was performed on the Trf2 and 53BP1 images separately to identify individual foci. Nuclei were excluded if they contained multiple foci combined into one (Trf2 and 53BP1) or if they contained Յ5 foci (Trf2 only). An intersection layer was created from the Trf2 and 53BP1 layers to identify colocalized foci, and the data for each ROI layer were exported to a data table. Descriptive statistics were generated, and data were analyzed by Kruskal-Wallis nonparametric analysis of variance with multiplecomparison corrections performed using GraphPad Prism 8. Data were visualized as a box plot with whiskers covering all values for each data set. Representative nuclei were selected in Nikon NIS-Elements software, and image contrast was enhanced for visual presentation postanalysis.
Coimmunoprecipitation. Immunoprecipitations were carried out using either anti-c-myc-agarose (Pierce 20168) or anti-FLAG M2 affinity gel (Sigma A2220). A 20-l volume of bead slurry per reaction was washed with PBS and equilibrated in CHAPS buffer before addition of 45 l of lysate. Samples were incubated in an end-over-end mixer at 4°C for 2 h. Beads were pelleted, washed 4 times with 300 l 1ϫ CHAPS buffer, and resuspended in 2ϫ LDS loading dye for Western blot analysis.

SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/MCB .00593-18.